Last reviewed · How we verify

CK-2017357 — Competitive Intelligence Brief

CK-2017357 (CK-2017357) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cardiac myosin inhibitor. Area: Cardiovascular.

phase 2 cardiac myosin inhibitor cardiac myosin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CK-2017357 (CK-2017357) — Cytokinetics. CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CK-2017357 TARGET CK-2017357 Cytokinetics phase 2 cardiac myosin inhibitor cardiac myosin
Camzyos MAVACAMTEN Bristol-Myers Squibb marketed Cardiac Myosin Inhibitor [EPC] cardiac myosin 2022-01-01
Omecamtiv Mecarbil (OM) Omecamtiv Mecarbil (OM) Cytokinetics phase 3 Cardiac myosin activator Cardiac myosin
TNX-103 TNX-103 Tenax Therapeutics, Inc. phase 3 Cardiac myosin inhibitor Cardiac myosin
Camzyos MYK-461 Myokardia Inc marketed Cardiac Myosin Inhibitor [EPC] Myosin-7 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (cardiac myosin inhibitor class)

  1. Cytokinetics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CK-2017357 — Competitive Intelligence Brief. https://druglandscape.com/ci/ck-2017357. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: